Company / EPS (Diluted)
Inhibikase Therapeutics, Inc. EPS (Diluted) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.16
FY2024
5-year range
-$4.28 / -$0.35
FY2021-FY2024
Trend
+26.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) returned to growth in FY2024 after 2 years of decline, reaching $-3.16.
Based on SEC 10-K filings.
-3.16 in FY2024.
Declined from $-0.81 to $-3.16 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, eps (diluted) increased 26.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$3.16 | +26.2% |
| FY2023 | -$4.28 | -428.4% |
| FY2022 | -$0.81 | -131.4% |
| FY2021 | -$0.35 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026